Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tranylcypromine withdrawal phenomena

M T Halle1, S C Dilsaver

  • 1Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center, Houston.

Journal of Psychiatry & Neuroscience : JPN
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The interaction of a benzodiazepine receptor antagonist (Ro15-1788) with GABA and GABA receptor antagonists at the GABA(A) receptor chloride-ionophore complex.

Neurochemistry international·2010
Same author

Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants.

Journal of affective disorders·2002
Same author

Unsuspected depressive mania in pre-pubertal Hispanic children referred for the treatment of 'depression' with history of social 'deviance'.

Journal of affective disorders·2002
Same author

ECT in mixed affective states: a case series.

The journal of ECT·2000
Same author

Mania: differential effects of previous depressive and manic episodes on response to treatment.

Acta psychiatrica Scandinavica·2000
Same author

Mania: gender, transmitter function, and response to treatment.

Psychiatry research·2000

Abruptly stopping tranylcypromine can cause severe withdrawal symptoms, including depression and cognitive impairment. Physician supervision is crucial during tranylcypromine dose reduction or discontinuation.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Psychiatry

Background:

  • Tranylcypromine is a monoamine oxidase inhibitor (MAOI) used to treat depression.
  • MAOIs carry risks associated with abrupt cessation.
  • Understanding withdrawal syndromes is vital for patient safety.

Observation:

  • Five patients experienced withdrawal syndromes upon reducing or stopping tranylcypromine.
  • Symptoms included severe depression and cognitive impairment.
  • Withdrawal effects ranged from mild discomfort to incapacitation.

Findings:

  • Dose reduction or discontinuation of tranylcypromine can precipitate significant adverse effects.
  • Reported symptoms highlight the neurobiological impact of MAOI withdrawal.

Related Experiment Videos

  • Patient cases illustrate the severity and variability of tranylcypromine withdrawal.

    • Implications:

    • Physician supervision is essential when adjusting tranylcypromine dosage.
    • Clinicians should be vigilant for withdrawal symptoms in patients on tranylcypromine.
    • This underscores the need for careful medication management in psychiatric care.